dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Athanasiades, A. | en |
dc.contributor.author | Kalogera-Fountzila, Anna | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Dombros, N. | en |
dc.contributor.author | Loannidis, I. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Athanasiades, A. | en |
dc.creator | Kalogera-Fountzila, Anna | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Dombros, N. | en |
dc.creator | Loannidis, I. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.date.accessioned | 2018-06-22T09:53:04Z | |
dc.date.available | 2018-06-22T09:53:04Z | |
dc.date.issued | 1997 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41641 | |
dc.description.abstract | 37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg · min/ml every 4 weeks with G-CSF support. There were 5 (14%, 95% CI 3-25%) complete and 11 (30%, 95% CI 15-45%) partial responders. Median duration of response was 11.5 months (range 5.2-16.8+), median time to progression 8 months (range 0.26-16.8+) and median survival 12 months (range 0.5-19.6+). Grade 3-4 leucopenia (27%), thrombocytopenia (10%) and diarrhoea (5%) were noted. In conclusion, the combination of paclitaxel and carboplatin is active and well tolerated in patients with advanced breast cancer resistant to anthracyclines. | en |
dc.language.iso | eng | en |
dc.source | European journal of cancer | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast neoplasms | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Chemotherapy | en |
dc.subject | Neoplasm | en |
dc.subject | Priority journal | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Drug efficacy | en |
dc.subject | Drug resistance | en |
dc.subject | Infection | en |
dc.subject | Leukopenia | en |
dc.subject | Ondansetron | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Phytogenic | en |
dc.subject | Recombinant granulocyte colony stimulating factor | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Treatment outcome | en |
dc.subject | Infusions | en |
dc.subject | Intravenous | en |
dc.subject | Cimetidine | en |
dc.subject | Dexamethasone | en |
dc.subject | Dimetindene | en |
dc.subject | Mitoxantrone | en |
dc.subject | Carboplatin | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Subcutaneous drug administration | en |
dc.subject | Vomiting | en |
dc.subject | Breast cancer | en |
dc.subject | Nausea | en |
dc.subject | Anthracycline derivative | en |
dc.subject | Paclitaxel | en |
dc.subject | Adolescent | en |
dc.subject | Cancer resistance | en |
dc.subject | Intramuscular drug administration | en |
dc.subject | Neuropathy | en |
dc.title | Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the hellenic cooperative oncology group | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/S0959-8049(97)00217-7 | |
dc.description.volume | 33 | |
dc.description.issue | 11 | |
dc.description.startingpage | 1893 | |
dc.description.endingpage | 1895 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.contributor.orcid | Kalogera-Fountzila, Anna [0000-0002-6801-3129] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713|0000-0002-6801-3129 | |